• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 23, 2016

View Archived Issues

Evaluating the value proposition: NICE chief sets conciliatory tone

DUBLIN – Even if much of the focus of the inaugural Biopharma Ambition meeting here was, as the name suggests, on how Ireland can compete to win more investment from the global biopharma industry, scheduling Sir Andrew Dillon, CEO of England's National Institute for Health and Care Excellence (NICE), as the final speaker in the final plenary session, suggested a certain amount of realism on the part of the conference organizers. Read More

Iomx raises $45M for tumor-derived immune checkpoint targets

DUBLIN – A mere four months after its formation, German startup Iomx Therapeutics GmbH raised €40 million (US$44.6 million) in a series A round to develop antibody-based therapeutics against tumor-derived immune checkpoint targets. Read More

One target for multiple lysosomal storage diseases

Preclinical work by researchers from Danish Orphazyme ApS has demonstrated that targeting heat-shock protein 70 (Hsp70) could alleviate a number of different lysosomal storage diseases, a group of several dozen rare to ultra-rare disorders united by mutations in proteins that lead to problems with cellular waste disposal. Read More

Four-closure: Seelos deal with Ligand brings motley crew, hinges on financing

Newly formed Seelos Therapeutics Inc. is "pretty well positioned to raise money," Ligand Pharmaceuticals Inc. President Matthew Foehr told BioWorld Today, and that's what Seelos needs to do in the four-piece licensing deal with San Diego-based Ligand. Read More

FDA's eteplirsen nod unprecedented, troubling

Let's hear a round of applause for a milestone in U.S. drug development, and for dramatic effect pipe in a little background music from Jerry Lewis singing "Smile," the opening theme song from his annual Muscular Dystrophy Association Telethon. Read More

Financings

Sarepta Therapeutics Inc., of Cambridge, Mass., said it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in a public offering and will grant underwriters a 30-day option to purchase up to an additional 15 percent of shares. Read More

Other news to note

Avacta Group plc, of Wetherby, U.K., reported preclinical results from in vivo studies of its Affimer molecules. Read More

In the clinic

Kadmon Holdings Inc., of New York, said the first patient was dosed in a 150-participant, double-blind, placebo-controlled phase II trial of KD025, the company's oral inhibitor of Rho-associated coiled-coil kinase 2, in moderate to severe chronic plaque psoriasis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe